The T‑SPOT.TB test is based on the in vitro ELISPOT assay developed at the University of Oxford, UK. The T‑SPOT.TB test also incorporates the discoveries of the research group at the Statens Serum Institut, Copenhagen, Denmark.
This pioneering technology has been described in over 80 peer-reveiwed publications showing the test's excellent performance in a wide variety of clinical and epidemiological settings including:
- Latent TB infection
- TB disease (including pulmonary and extrapulmonary TB)
- HIV positive and HIV negative patients
- Anti-TNFα treated patients
- Dialysis and transplant patients
- Babies, children, adults and the elderly
- Malnourished individuals
- Low prevalence countries in the developed world and high prevalence countries in the developing world
- Healthcare worker screening
In addition to the published studies above, many further studies using the technology have been completed (pending publication) or are ongoing. The results of these studies will be published as soon as possible. Studies have been designed to investigate the use of T‑SPOT.TB in specific patient groups, and to demonstrate the superior sensitivity of the T-SPOT technique over other laboratory methods.
To see a summary of key clinical studies click here.
